Zobrazeno 1 - 10
of 145
pro vyhledávání: '"Laura, Pizzuti"'
Autor:
Francesca Sofia Di Lisa, Alice Villa, Lorena Filomeno, Teresa Arcuri, Benito Chiofalo, Giuseppe Sanguineti, Laura Pizzuti, Eriseld Krasniqi, Maddalena Barba, Domenico Sergi, Francesco Lombardo, Francesco Romanelli, Claudio Botti, Giovanni Zoccali, Gennaro Ciliberto, Patrizia Vici
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Transgender individuals exhibit a higher prevalence of cancer-related risk factors, such as substance abuse and sexually transmitted infections. These factors, coupled with suboptimal adherence to cancer screening recommendations, may lead to a highe
Externí odkaz:
https://doaj.org/article/0b25398f4cc04772a41b2348d2e1a732
Autor:
Giulia Bon, Eriseld Krasniqi, Manuela Porru, Lorenzo D'Ambrosio, Stefano Scalera, Marcello Maugeri-Saccà, Francesca Sofia Di Lisa, Lorena Filomeno, Teresa Arcuri, Andrea Botticelli, Daniele Santini, Maria Agnese Fabbri, Giuliana D'Auria, Claudio Pulito, Giovanni Blandino, Caterina Marchiò, Maddalena Barba, Gennaro Ciliberto, Patrizia Vici, Laura Pizzuti
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 45, Iss , Pp 100937- (2023)
The therapeutic scenario of Human Epidermal Growth Factor Receptor 2 positive advanced breast cancer (ABC) has been recently enriched by a number of innovative agents, which are reshaping treatment sequence. While randomized trials have documented an
Externí odkaz:
https://doaj.org/article/f29fae04ef374dc0bbefa7906732c0e1
Autor:
Giulia Mentrasti, Luca Cantini, Patrizia Vici, Nicola D'Ostilio, Nicla La Verde, Rita Chiari, Vittorio Paolucci, Sonia Crocetti, Chiara De Filippis, Federica Pecci, Francesca Sofia Di Lisa, Donatella Traisci, Maria Silvia Cona, Linda Nicolardi, Laura Pizzuti, Simona Gildetti, Simone Oldani, Arianna Della Mora, Marco Luigi Bruno Rocchi, Rossana Berardi
Publikováno v:
Breast, Vol 65, Iss , Pp 164-171 (2022)
Purpose: Breast cancer (BC) patients’ (pts) management was affected by a global reorganization after Coronavirus disease 2019 (COVID-19). Our multicenter study aimed to assess the impact of COVID-19 on access to diagnosis, staging and treatment for
Externí odkaz:
https://doaj.org/article/5a1c9c5ec8c048d8a0f712de03031afa
Autor:
Alessio Annovazzi, Sandra Rea, Daria Maccora, Laura Pizzuti, Gianluigi Ferretti, Patrizia Vici, Federico Cappuzzo, Rosa Sciuto
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
ObjectiveThe addition of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) to endocrine therapy impressively improved the outcome of patients with hormone receptor-positive metastatic breast cancer. Despite their great efficacy, not all patients respo
Externí odkaz:
https://doaj.org/article/34c63118bba74dd5ae45516389f04982
Autor:
Agnese Fabbri, Fabrizio Nelli, Andrea Botticelli, Diana Giannarelli, Eleonora Marrucci, Cristina Fiore, Antonella Virtuoso, Simone Scagnoli, Simona Pisegna, Daniele Alesini, Valentina Sini, Armando Orlandi, Alessandra Fabi, Federico Piacentini, Luca Moscetti, Giuliana D’Auria, Teresa Gamucci, Marco Mazzotta, Laura Pizzuti, Patrizia Vici, Elisabetta Cretella, Paola Scavina, Annalisa La Cesa, Mara Persano, Francesco Atzori, Enzo Maria Ruggeri
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
PurposeClinical trials have shown a significant increase in pathologic complete response (pCR) with the addition of pertuzumab to neoadjuvant chemotherapy for patients with early-stage HER-2 positive breast cancer. To date, limited studies have exami
Externí odkaz:
https://doaj.org/article/26649e667aa0456fbd64724a36c65d33
Autor:
Francesca Sofia Di Lisa, Eriseld Krasniqi, Laura Pizzuti, Maddalena Barba, Katia Cannita, Ugo De Giorgi, Fulvio Borella, Jennifer Foglietta, Anna Cariello, Antonella Ferro, Elisa Picardo, Marco Mitidieri, Valentina Sini, Simonetta Stani, Giuseppe Tonini, Daniele Santini, Nicla La Verde, Anna Rita Gambaro, Antonino Grassadonia, Nicola Tinari, Ornella Garrone, Giuseppina Sarobba, Lorenzo Livi, Icro Meattini, Giuliana D’Auria, Matteo Vergati, Teresa Gamucci, Mirco Pistelli, Rossana Berardi, Emanuela Risi, Francesco Giotta, Vito Lorusso, Lucia Rinaldi, Salvatore Artale, Marina Elena Cazzaniga, Fable Zustovich, Federico Cappuzzo, Lorenza Landi, Rosalba Torrisi, Simone Scagnoli, Andrea Botticelli, Andrea Michelotti, Beatrice Fratini, Rosa Saltarelli, Ida Paris, Margherita Muratore, Alessandra Cassano, Lorenzo Gianni, Valeria Gaspari, Enzo Maria Veltri, Federica Zoratto, Elena Fiorio, Maria Agnese Fabbri, Marco Mazzotta, Enzo Maria Ruggeri, Rebecca Pedersini, Maria Rosaria Valerio, Lorena Filomeno, Mauro Minelli, Paola Scavina, Mimma Raffaele, Antonio Astone, Roy De Vita, Marcello Pozzi, Ferdinando Riccardi, Filippo Greco, Luca Moscetti, Monica Giordano, Marcello Maugeri-Saccà, Alessandro Zennaro, Claudio Botti, Fabio Pelle, Sonia Cappelli, Flavia Cavicchi, Enrico Vizza, Giuseppe Sanguineti, Federica Tomao, Enrico Cortesi, Paolo Marchetti, Silverio Tomao, Iolanda Speranza, Isabella Sperduti, Gennaro Ciliberto, Patrizia Vici
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundIn triple negative breast cancer patients treated with neoadjuvant chemotherapy, residual disease at surgery is the most relevant unfavorable prognostic factor. Current guidelines consider the use of adjuvant capecitabine, based on the resu
Externí odkaz:
https://doaj.org/article/9054ef5212d94639a5488c4656e59bc0
Autor:
Laura Pizzuti, Maddalena Barba, Marco Mazzotta, Eriseld Krasniqi, Marcello Maugeri-Saccà, Teresa Gamucci, Rossana Berardi, Lorenzo Livi, Corrado Ficorella, Clara Natoli, Enrico Cortesi, Daniele Generali, Nicla La Verde, Alessandra Cassano, Emilio Bria, Luca Moscetti, Andrea Michelotti, Vincenzo Adamo, Claudio Zamagni, Giuseppe Tonini, Domenico Sergi, Daniele Marinelli, Giancarlo Paoletti, Silverio Tomao, Andrea Botticelli, Paolo Marchetti, Nicola Tinari, Antonino Grassadonia, Maria Rosaria Valerio, Rosanna Mirabelli, Maria Agnese Fabbri, Nicola D’Ostilio, Enzo Veltri, Domenico Corsi, Ornella Garrone, Ida Paris, Giuseppina Sarobba, Icro Meattini, Mirco Pistelli, Francesco Giotta, Vito Lorusso, Carlo Garufi, Antonio Russo, Marina Cazzaniga, Pietro Del Medico, Mario Roselli, Angela Vaccaro, Letizia Perracchio, Anna di Benedetto, Theodora Daralioti, Isabella Sperduti, Ruggero De Maria, Angelo Di Leo, Giuseppe Sanguineti, Gennaro Ciliberto, Patrizia Vici
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Abstract In metastatic breast cancer (mBC), the change of human epidermal growth factor receptor 2 (HER2) status between primary and metastatic lesions is widely recognized, however clinical implications are unknown. Our study address the question if
Externí odkaz:
https://doaj.org/article/480280eb7ab4458fa7a0a13c1dcceb2c
Autor:
Giulia Bon, Laura Pizzuti, Valentina Laquintana, Rossella Loria, Manuela Porru, Caterina Marchiò, Eriseld Krasniqi, Maddalena Barba, Marcello Maugeri-Saccà, Teresa Gamucci, Rossana Berardi, Lorenzo Livi, Corrado Ficorella, Clara Natoli, Enrico Cortesi, Daniele Generali, Nicla La Verde, Alessandra Cassano, Emilio Bria, Luca Moscetti, Andrea Michelotti, Vincenzo Adamo, Claudio Zamagni, Giuseppe Tonini, Giacomo Barchiesi, Marco Mazzotta, Daniele Marinelli, Silverio Tomao, Paolo Marchetti, Maria Rosaria Valerio, Rosanna Mirabelli, Antonio Russo, Maria Agnese Fabbri, Nicola D’Ostilio, Enzo Veltri, Domenico Corsi, Ornella Garrone, Ida Paris, Giuseppina Sarobba, Francesco Giotta, Carlo Garufi, Marina Cazzaniga, Pietro Del Medico, Mario Roselli, Giuseppe Sanguineti, Isabella Sperduti, Anna Sapino, Ruggero De Maria, Carlo Leonetti, Angelo Di Leo, Gennaro Ciliberto, Rita Falcioni, Patrizia Vici
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 39, Iss 1, Pp 1-14 (2020)
Abstract Background HER2-targeting agents have dramatically changed the therapeutic landscape of HER2+ advanced breast cancer (ABC). Within a short time frame, the rapid introduction of new therapeutics has led to the approval of pertuzumab combined
Externí odkaz:
https://doaj.org/article/4d34ed52da98405db47bb21f0f6da119
Autor:
Andrea Botticelli, Agnese Fabbri, Michela Roberto, Daniele Alesini, Alessio Cirillo, Giuliana D’Auria, Eriseld Krasniqi, Eleonora Marrucci, Margherita Muratore, Francesco Pantano, Laura Pizzuti, Ilaria Portarena, Rosalina Rossi, Simone Scagnoli, Paolo Marchetti
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
The recent addition of cyclin-dependent kinase 4 (CDK4) and CDK6 inhibitors to endocrine therapy has remarkably improved the outcome of patients affected with hormone receptor positive (HR+), human epidermal grow factor receptor 2 negative (HER2 -) a
Externí odkaz:
https://doaj.org/article/d76b983b99da478b9b49de9ccce936c1
Autor:
Laura Pizzuti, Eriseld Krasniqi, Isabella Sperduti, Maddalena Barba, Teresa Gamucci, Maria Mauri, Enzo Maria Veltri, Icro Meattini, Rossana Berardi, Francesca Sofia Di Lisa, Clara Natoli, Mirco Pistelli, Laura Iezzi, Emanuela Risi, Nicola D’Ostilio, Silverio Tomao, Corrado Ficorella, Katia Cannita, Ferdinando Riccardi, Alessandra Cassano, Emilio Bria, Maria Agnese Fabbri, Marco Mazzotta, Giacomo Barchiesi, Andrea Botticelli, Giuliana D’Auria, Anna Ceribelli, Andrea Michelotti, Antonio Russo, Beatrice Taurelli Salimbeni, Giuseppina Sarobba, Francesco Giotta, Ida Paris, Rosa Saltarelli, Daniele Marinelli, Domenico Corsi, Elisabetta Maria Capomolla, Valentina Sini, Luca Moscetti, Lucia Mentuccia, Giuseppe Tonini, Mimma Raffaele, Luca Marchetti, Mauro Minelli, Enzo Maria Ruggeri, Paola Scavina, Olivia Bacciu, Nello Salesi, Lorenzo Livi, Nicola Tinari, Antonino Grassadonia, Angelo Fedele Scinto, Rosalinda Rossi, Maria Rosaria Valerio, Elisabetta Landucci, Simonetta Stani, Beatrice Fratini, Marcello Maugeri-Saccà, Michele De Tursi, Angela Maione, Daniele Santini, Armando Orlandi, Vito Lorusso, Enrico Cortesi, Giuseppe Sanguineti, Paola Pinnarò, Federico Cappuzzo, Lorenza Landi, Claudio Botti, Federica Tomao, Sonia Cappelli, Giulia Bon, Fabio Pelle, Flavia Cavicchi, Elena Fiorio, Jennifer Foglietta, Simone Scagnoli, Paolo Marchetti, Gennaro Ciliberto, Patrizia Vici
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Background: The evolution of therapeutic landscape of human epidermal growth factor receptor-2 (HER2)-positive breast cancer (BC) has led to an unprecedented outcome improvement, even if the optimal sequence strategy is still debated. To address this
Externí odkaz:
https://doaj.org/article/8be0edebe30b47389bcf83b804b70b94